Revenue Performance - Total revenue for the year ended December 31, 2025, was HKD 336,113,000, a decrease of 12.0% from HKD 382,090,000 in 2024[2] - Revenue from Hong Kong concentrated Chinese medicine granules was HKD 192,317,000, down 7.4% from HKD 207,591,000 in the previous year[2] - Revenue from Chinese medicine health products increased by 9.8% to HKD 92,557,000, compared to HKD 84,302,000 in 2024[2] - Revenue from the sale of concentrated Chinese medicine granules was HKD 230,673,000 in 2025, down from HKD 284,706,000 in 2024, representing a decline of 19.0%[27] - The segment revenue from Chinese herbal health products was HKD 92,557,000 in 2025, an increase of 13.1% from HKD 82,017,000 in 2024[27] - The revenue generated from the operation of the company's clinics was HKD 51.2 million, a decrease of HKD 5.1 million or 9.0% compared to the previous year[60] Profit and Loss - The company reported a gross profit of HKD 180,156,000, a decline of 12.2% from HKD 205,142,000 in 2024[4] - The net loss for the year was HKD 35,223,000, slightly improved from a loss of HKD 35,439,000 in the previous year[4] - The company reported a total operating profit of HKD 59,454,000 for 2025, down from HKD 70,037,000 in 2024, a decrease of 15.5%[25][26] - The group recorded a loss attributable to the owners of the company of HKD 35.2 million for the year ended December 31, 2025, with a net current liability of HKD 252.3 million[10] - The group’s net loss for the year ended December 31, 2025, was HKD 35.2 million, a slight decrease from a net loss of HKD 35.4 million in the previous year[70] Assets and Liabilities - Total assets less current liabilities amounted to HKD 214,343,000, down from HKD 224,658,000 in 2024[7] - Non-current assets totaled HKD 466,672,000, an increase from HKD 447,284,000 in 2024[6] - The company’s equity increased to HKD 130,484,000 from HKD 111,198,000 in 2024[7] - As of December 31, 2025, the current portion of interest-bearing bank and other borrowings amounted to HKD 268.3 million, while cash and cash equivalents were only HKD 16.2 million[10] - The total interest-bearing bank and other borrowings amounted to HKD 323,816,000 in 2025, down from HKD 339,710,000 in 2024[46] - The company’s total assets pledged as collateral for interest-bearing bank loans were valued at HKD 208,507,000 in 2025, down from HKD 253,426,000 in 2024[48] Cash Flow and Financing - The company’s cash and cash equivalents increased to HKD 16,170,000 from HKD 12,794,000 in the previous year[6] - The company’s cash flow management is reflected in the net cash flow from operating activities, which showed a significant change from a net outflow of HKD 1,480,000 in 2025 compared to an inflow of HKD 5,387,000 in 2024[36] - The group has unutilized bank financing of HKD 28.5 million as of December 31, 2025, which is expected to be extended for another year[10] - The group has defaulted on certain covenants of bank loans totaling HKD 25.2 million and has overdue repayments of HKD 24.4 million, leading to a potential immediate repayment of borrowings amounting to HKD 49.6 million at the lender's discretion[10] - The company is actively negotiating with banks to amend financing covenants, with reasonable expectations of securing future bank financing[47] Corporate Governance - The company has adopted the corporate governance code as per the Stock Exchange Listing Rules, ensuring compliance with all applicable provisions[93] - The roles of the Chairman and CEO are not separated as of December 31, 2025, due to the nature of the business and the expertise of the current CEO[94] - The Audit Committee consists of three independent non-executive directors, ensuring adequate independence and oversight[95] - The independent auditor has agreed that the preliminary performance announcement data for the year ending December 31, 2025, is consistent with the group's consolidated financial statements[97] - The audit committee has reviewed the group's financial performance for the year ending December 31, 2025, and believes it complies with relevant accounting standards and regulations[96] Future Outlook and Risks - The ability to continue as a going concern is subject to significant uncertainties, including the successful implementation of the board's plans and measures[11] - Forward-looking statements regarding the group's financial condition and business performance are subject to known and unknown risks and uncertainties[105] - If the group fails to implement its plans, it may need to adjust the carrying value of its assets and liabilities, which has not been reflected in the consolidated financial statements[14] Shareholder Information - The board of directors has decided not to recommend a final dividend for the year ending December 31, 2025[101] - The annual general meeting is scheduled for May 27, 2026, with a suspension of share transfer registration from May 21 to May 27, 2026[102][103] - There were no purchases, sales, or redemptions of the company's listed securities during the year ending December 31, 2025[99]

培力農本方有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1498） 完成根據一般授權發行可換股債券 茲提述培力農本方有限公司（「本公司」）日期為二零二六年二月二十六日之公 告，內容有關建議根據一般授權發行可換股債券（「該公告」）。除另有說明外， 本公告所用詞彙與該公告所界定者具有相同涵義。 完成發行可換股債券 董事會欣然宣佈，可換股債券認購協議項下之所有條件均已達成。可換股債 券認購協議已於二零二六年三月二十三日完成，根據其條款及條件，本金總 額為20,000,000港元的可換股債券已發行予認購人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，且明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 本公告僅供參考，並不構成收購、購買或認購股份或本公司其他證券的邀請 或要約。 PURAPHARM CORPORATION LIMITED 附註： 3 (1) 陳先生及文女士實益擁有Joint Partners Investments Limited 50%及50%已發行股本，而 Joint Par ...

培力農本方有限公司(「本公司」，連同其附屬公司統稱「本集團」)董事會(「董事會」)謹此宣 佈，董事會會議將於二零二六年三月二十五日（星期三）舉行，以（其中包括）考慮及酌情批准 本集團截至二零二五年十二月三十一日止年度的全年業績(「全年業績」) ，刊發全年業績公告， 並考慮派付末期股息（如有）。 承董事會命 培力農本方有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，且明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 PURAPHARM CORPORATION LIMITED 培力農本方有限公司 (於開曼群島註冊成立的有限公司) (股份代號：1498) 董事會會議通告 主席兼執行董事 陳宇齡 香港，二零二六年三月十三日 於本公告日期，執行董事為陳宇齡先生、文綺慧女士及蔡鑑彪博士；非執 行 董 事 為 梁 國 強 先 生 及 董 子 銘 先 生；及 獨 立 非 執 行 董 事 為 洪 廷 安 博 士、 梁念堅博士及徐立之教授。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.2.0 公司名稱: 培力農本方有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01498 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000,000 | USD | | 0.001 | USD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000,000 | USD | | 0. ...

Core Viewpoint - The company, Peili Nongbenfang (01498), has entered into a conditional subscription agreement for convertible bonds with Protoss Global Opportunities Fund, aiming to raise HKD 20 million for various operational and developmental purposes [2] Group 1: Convertible Bonds Agreement - The company has agreed to issue convertible bonds with a principal amount of HKD 20 million, convertible at a price of HKD 0.49 per share [2] - The total proceeds from the convertible bonds are approximately HKD 20 million, with a net amount of about HKD 19.85 million after expenses [2] Group 2: Use of Proceeds - Approximately HKD 10 million of the net proceeds will be allocated for general working capital, including the procurement of raw herbs, employee costs, and rental expenses [2] - Around HKD 5 million will be used to repay existing bank loans, aiming to reduce the company's debt-to-equity ratio and lower financing costs [2] - The remaining proceeds will focus on expanding the company's existing business, specifically for upgrading production facilities and supporting the research and development of new concentrated traditional Chinese medicine granules [2]

Core Viewpoint - The company, Peili Nongbenfang (01498), has entered into a subscription agreement for convertible bonds with Protoss Global Opportunities Fund, agreeing to issue bonds worth HKD 20 million at a conversion price of HKD 0.49 per share [1] Group 1: Convertible Bonds - The total amount of the convertible bond subscription is approximately HKD 20 million, with a net amount of about HKD 19.85 million [1] - The company plans to utilize the net proceeds from the convertible bond subscription for various purposes, including operational funding and debt repayment [1] Group 2: Fund Allocation - Approximately HKD 10 million will be allocated for general operational expenses, including the procurement of raw herbs, employee costs, and rental expenses [1] - Around HKD 5 million will be used to repay existing bank loans, aiming to reduce the group's debt-to-equity ratio and lower financing costs [1] - The remaining proceeds will focus on expanding the group's existing business, specifically for upgrading production facilities and supporting the research and development of new concentrated traditional Chinese medicine granules [1]

Group 1 - The company, Peili Nongbenfang (01498.HK), announced a subscription agreement for convertible bonds with Protoss Global Opportunities Fund, amounting to HKD 20 million [1] - The convertible bonds can be converted into shares at a conversion price of HKD 0.49 per share, which represents a premium of approximately 46.27% over the closing price of HKD 0.335 reported on the Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，且明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 培力農本方有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1498） 根據一般授權發行可換股債券 認購可換股債券 於二零二六年二月二十六日（交易時段後），本公司與可換股債券認購人訂 立可換股債券認購協議，據此，可換股債券認購人已有條件同意認購而本公 司已有條件同意發行本金額為20,000,000港元的可換股債券，可按每股轉換 股份0.49港元的換股價轉換為轉換股份。 本公告僅供參考，並不構成收購、購買或認購股份或本公司其他證券的邀請 或要約。 PURAPHARM CORPORATION LIMITED 可換股債券認購事項須待（其中包括）聯交所批准於行使可換股債券所附轉 換權時獲配發及發行的轉換股份上市及買賣後，方可作實。 1 轉換股份將根據一般授權發行及配發。 本公司將不會申請可換股債券於聯交所或任何其他證券交易所上市或買 賣。本公司將向聯交所申請批准轉換股份上市及買賣。 可換股債券認購事項的完 ...

致：香港交易及結算所有限公司 公司名稱: 培力農本方有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01498 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000,000 | USD | | 0.001 | USD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000,000 | USD | | 0.001 | USD | | 5,000,000,000 | 本月底法定/註冊股本總額： USD 5,000,000,000 FF301 股份發行人及根據《上市規則》第十九B ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 培力農本方有限公司 本月底法定/註冊股本總額： USD 5,000,000,000 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01498 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 535,897,647 | | 0 | | 535,897,647 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 535,897,647 | | 0 | | 535,897,647 | 第 2 ...